RPS6KA2, ribosomal protein S6 kinase A2, 6196

N. diseases: 54; N. variants: 12
Disease: Malignant Neoplasms ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 AlteredExpression group BEFREE These findings establish RSK2 as an obligate participant of ERα-mediated transcriptional programs, tumorigenesis, and divergent patient responses to antiestrogen therapies.<b>Significance:</b> Nuclear accumulation of active RSK drives a protumorigenic transcriptional program and renders ER<sup>+</sup> breast cancer susceptible to endocrine-based therapies.<i>Cancer Res; 78(8); 2014-25.©2018 AACR</i>. 29351904 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Although the RSKs have a high degree of sequence homology, their functional differences in cancer are of great interest. 28718440 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Taken together, these results indicate that the phosphorylation of EphA2 at Ser-897 is controlled by RSK and the RSK-EphA2 axis might contribute to cell motility and promote tumour malignant progression. 26158630 2015
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells. 26011941 2015
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 AlteredExpression group BEFREE Detailed experimental validation by quantitative real-time RT-PCR of five putative cancer related sense-antisense transcript pairs revealed a single candidate tumor suppressor gene (RPS6KA2) whose expression levels display marked cancer-related changes that are likely mediated by its antisense RNA in a breast cancer cell line model. 19287968 2009